JP2014507445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507445A5 JP2014507445A5 JP2013555599A JP2013555599A JP2014507445A5 JP 2014507445 A5 JP2014507445 A5 JP 2014507445A5 JP 2013555599 A JP2013555599 A JP 2013555599A JP 2013555599 A JP2013555599 A JP 2013555599A JP 2014507445 A5 JP2014507445 A5 JP 2014507445A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- aryl
- heteroaryl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC(C*C1C(C)(C2(C(C)C)C3*CC3)C2(C2C(*)C*2)C(C2C(C)C2)(C2C(C)CC2)C1C)C(C)(C)C1***C1 Chemical compound CCC(C*C1C(C)(C2(C(C)C)C3*CC3)C2(C2C(*)C*2)C(C2C(C)C2)(C2C(C)CC2)C1C)C(C)(C)C1***C1 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446729P | 2011-02-25 | 2011-02-25 | |
| US61/446,729 | 2011-02-25 | ||
| PCT/US2012/026517 WO2012116279A1 (en) | 2011-02-25 | 2012-02-24 | Cannabinoid receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016221615A Division JP2017039773A (ja) | 2011-02-25 | 2016-11-14 | カンナビノイド受容体モジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507445A JP2014507445A (ja) | 2014-03-27 |
| JP2014507445A5 true JP2014507445A5 (OSRAM) | 2015-04-09 |
| JP6043733B2 JP6043733B2 (ja) | 2016-12-14 |
Family
ID=46000314
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013555599A Expired - Fee Related JP6043733B2 (ja) | 2011-02-25 | 2012-02-24 | カンナビノイド受容体モジュレーター |
| JP2016221615A Withdrawn JP2017039773A (ja) | 2011-02-25 | 2016-11-14 | カンナビノイド受容体モジュレーター |
| JP2018106019A Withdrawn JP2018162260A (ja) | 2011-02-25 | 2018-06-01 | カンナビノイド受容体モジュレーター |
| JP2020028389A Withdrawn JP2020079302A (ja) | 2011-02-25 | 2020-02-21 | カンナビノイド受容体モジュレーター |
| JP2022029449A Pending JP2022066289A (ja) | 2011-02-25 | 2022-02-28 | カンナビノイド受容体モジュレーター |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016221615A Withdrawn JP2017039773A (ja) | 2011-02-25 | 2016-11-14 | カンナビノイド受容体モジュレーター |
| JP2018106019A Withdrawn JP2018162260A (ja) | 2011-02-25 | 2018-06-01 | カンナビノイド受容体モジュレーター |
| JP2020028389A Withdrawn JP2020079302A (ja) | 2011-02-25 | 2020-02-21 | カンナビノイド受容体モジュレーター |
| JP2022029449A Pending JP2022066289A (ja) | 2011-02-25 | 2022-02-28 | カンナビノイド受容体モジュレーター |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US20140206649A1 (OSRAM) |
| EP (2) | EP2678318A1 (OSRAM) |
| JP (5) | JP6043733B2 (OSRAM) |
| CN (2) | CN103492369B (OSRAM) |
| AU (1) | AU2012222149B2 (OSRAM) |
| DK (1) | DK3385252T3 (OSRAM) |
| ES (1) | ES2929977T3 (OSRAM) |
| IL (2) | IL227779A0 (OSRAM) |
| MX (2) | MX392150B (OSRAM) |
| PT (1) | PT3385252T (OSRAM) |
| WO (1) | WO2012116279A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4036082A1 (en) | 2009-08-28 | 2022-08-03 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| WO2012116277A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| EP2678318A1 (en) | 2011-02-25 | 2014-01-01 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| AU2012222146B2 (en) * | 2011-02-25 | 2017-05-11 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators) |
| JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
| EP2845625A1 (en) * | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| UA124626C2 (uk) * | 2016-04-10 | 2021-10-20 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СЕЛЕКТИВНИМИ АГОНІСТАМИ РЕЦЕПТОРА СВ<sub>2</sub> |
| MX2019013311A (es) | 2017-05-08 | 2020-08-03 | Arena Pharm Inc | Compuestos y metodos para el tratamiento del dolor visceral. |
| CN114391010A (zh) * | 2019-09-12 | 2022-04-22 | 四川海思科制药有限公司 | 一种三环吡唑衍生物及其制备 |
| TWI768465B (zh) * | 2019-09-12 | 2022-06-21 | 大陸商四川海思科製藥有限公司 | 四氫吲唑衍生物及其製備 |
| CN118843120A (zh) * | 2020-09-07 | 2024-10-25 | 中兴通讯股份有限公司 | 资源确定方法、通信节点及存储介质 |
| WO2023081857A1 (en) | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Condensed pyridazine amine derivatives treating sca3 |
| WO2023212237A1 (en) | 2022-04-27 | 2023-11-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| US20250304593A1 (en) | 2022-05-12 | 2025-10-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US236010A (en) | 1880-12-28 | Wilhelm effer | ||
| US5605906A (en) | 1995-03-24 | 1997-02-25 | Merck Frosst Canada, Inc. | Cannabinoid receptor agonists |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| US7308894B2 (en) | 1998-06-03 | 2007-12-18 | Scott Laboratories, Inc. | Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics |
| EE200100556A (et) | 1999-04-28 | 2003-02-17 | Aventis Pharma Deutschland Gmbh | Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks |
| EP1461027A4 (en) | 2001-12-07 | 2005-09-07 | Univ Virginia Commonwealth | TREATMENT OF NEOPLASIA |
| IL150302A (en) | 2002-01-31 | 2008-07-08 | Naim Menashe | Bicyclic cb2 cannabinoid receptor ligands |
| SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
| WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
| KR20070041717A (ko) * | 2004-07-12 | 2007-04-19 | 카딜라 핼쓰캐어 리미티드 | 카나비노이드 수용체 조절자인 트리시클릭 피라졸 유도체들 |
| FR2875230A1 (fr) | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| DE102004054666A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| PE20060949A1 (es) * | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| PL1902034T3 (pl) * | 2005-06-02 | 2011-09-30 | Glenmark Pharmaceuticals Sa | Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania |
| US7597910B2 (en) | 2005-08-20 | 2009-10-06 | Slgm Medical Research Institute | Compositions and methods for treating prostate disorders |
| EP1937646A1 (en) * | 2005-09-23 | 2008-07-02 | Janssen Pharmaceutica N.V. | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators |
| CA2654246A1 (en) | 2006-07-04 | 2008-01-10 | Janssen Pharmaceutica N.V. | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
| US7928123B2 (en) | 2006-09-25 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| US8481574B2 (en) | 2006-10-12 | 2013-07-09 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| US7928103B2 (en) | 2006-10-17 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| JP2010509201A (ja) | 2006-11-03 | 2010-03-25 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なカンナビノイド受容体リガンド、およびこれらを含む薬剤組成物、およびこれらの調製方法 |
| WO2008064054A2 (en) | 2006-11-21 | 2008-05-29 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| US9763894B2 (en) | 2006-12-05 | 2017-09-19 | Virginia Commonwealth University | Inflammation therapy |
| US20080161340A1 (en) | 2006-12-20 | 2008-07-03 | Cara Therapeutics, Inc. | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof |
| WO2008085302A1 (en) | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| WO2008109007A1 (en) | 2007-03-02 | 2008-09-12 | Cara Therapeutics, Inc. | Bridged phenanthridines |
| ES2548764T3 (es) | 2007-03-30 | 2015-10-20 | Janssen Pharmaceutica N.V. | Agonistas de cannabinoides de bencimidazol |
| US20090209536A1 (en) | 2007-06-17 | 2009-08-20 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| EP2170350B1 (en) | 2007-06-21 | 2013-09-11 | Cara Therapeutics, Inc. | Substituted imidazoheterocycles |
| US8338623B2 (en) | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
| EP2203171A2 (en) | 2007-08-21 | 2010-07-07 | Merck Sharp & Dohme Corp. | Cb2 receptor ligands for the treatment of pain |
| UA104010C2 (en) | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
| US7741350B1 (en) | 2009-01-28 | 2010-06-22 | Cara Therapeutics, Inc. | Bicyclic pyrazolo-heterocycles |
| JP6062633B2 (ja) * | 2009-01-28 | 2017-01-18 | カラ セラピューティクス インコーポレイテッド | 二環式ピラゾロ複素環類 |
| EP4036082A1 (en) * | 2009-08-28 | 2022-08-03 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| EP2678318A1 (en) | 2011-02-25 | 2014-01-01 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| WO2012116278A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| AU2012222146B2 (en) * | 2011-02-25 | 2017-05-11 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators) |
| WO2012116277A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
-
2012
- 2012-02-24 EP EP12716763.3A patent/EP2678318A1/en not_active Withdrawn
- 2012-02-24 JP JP2013555599A patent/JP6043733B2/ja not_active Expired - Fee Related
- 2012-02-24 CN CN201280020334.4A patent/CN103492369B/zh not_active Expired - Fee Related
- 2012-02-24 AU AU2012222149A patent/AU2012222149B2/en not_active Ceased
- 2012-02-24 DK DK18159738.6T patent/DK3385252T3/da active
- 2012-02-24 PT PT181597386T patent/PT3385252T/pt unknown
- 2012-02-24 WO PCT/US2012/026517 patent/WO2012116279A1/en not_active Ceased
- 2012-02-24 US US14/001,131 patent/US20140206649A1/en not_active Abandoned
- 2012-02-24 MX MX2017003054A patent/MX392150B/es unknown
- 2012-02-24 MX MX2013009764A patent/MX346644B/es active IP Right Grant
- 2012-02-24 CN CN201910180370.0A patent/CN109970708B/zh not_active Expired - Fee Related
- 2012-02-24 EP EP18159738.6A patent/EP3385252B8/en active Active
- 2012-02-24 ES ES18159738T patent/ES2929977T3/es active Active
-
2013
- 2013-08-04 IL IL227779A patent/IL227779A0/en unknown
-
2015
- 2015-12-02 US US14/956,586 patent/US9492447B2/en active Active
-
2016
- 2016-09-12 IL IL247779A patent/IL247779A/en active IP Right Grant
- 2016-09-29 US US15/279,576 patent/US9867822B2/en active Active
- 2016-11-14 JP JP2016221615A patent/JP2017039773A/ja not_active Withdrawn
-
2017
- 2017-12-05 US US15/831,742 patent/US20180280386A1/en not_active Abandoned
-
2018
- 2018-06-01 JP JP2018106019A patent/JP2018162260A/ja not_active Withdrawn
-
2019
- 2019-06-17 US US16/442,734 patent/US20200069681A1/en not_active Abandoned
-
2020
- 2020-02-21 JP JP2020028389A patent/JP2020079302A/ja not_active Withdrawn
-
2021
- 2021-09-17 US US17/478,274 patent/US11771695B2/en active Active
-
2022
- 2022-02-28 JP JP2022029449A patent/JP2022066289A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014507445A5 (OSRAM) | ||
| KR101677126B1 (ko) | 탄산염 프로드러그 및 그것의 사용 방법 | |
| JP5598775B2 (ja) | 癌の介入治療および根絶のためのｉｔｅとその類似体を含む医薬組成物 | |
| JP2011520977A5 (OSRAM) | ||
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| CA2544648C (en) | Analgesic compounds, their synthesis and pharmaceutical compositions containing them | |
| MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
| JP2018162260A (ja) | カンナビノイド受容体モジュレーター | |
| JP2000256194A (ja) | 核内レセプタ作動薬およびその効果増強剤 | |
| JP2018520195A5 (OSRAM) | ||
| WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
| CN103619330A (zh) | 用于治疗糖尿病的选择性雄激素受体调节剂 | |
| JP2016516773A5 (OSRAM) | ||
| AU2012262061A1 (en) | Compositions for sequential administration of opioid receptor agonists | |
| JP2012516288A (ja) | 薬物乱用抑制剤、方法および組成物 | |
| Tunn et al. | Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases | |
| US8598221B2 (en) | Synergistic combination of analgesic compounds | |
| CN109758452A (zh) | 胺类化合物治疗疼痛的医药用途 | |
| RU2010140888A (ru) | Улучшенные противораковые терапии | |
| JP2011502985A5 (OSRAM) | ||
| JP2013227347A5 (OSRAM) | ||
| US9592226B2 (en) | Solenopsin and derivatives, therapeutic compositions; and methods related thereto | |
| CZ2006623A3 (cs) | Kombinace deramciklanu a opioidů jako analgetik | |
| WO2015021324A1 (en) | Filanesib combined with pomalidomide displays enhanced anti-tumor activity | |
| Tammela et al. | Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: analysis of data from the ARADES and the ARAFOR trials |